US 12,391,748 B2
Decoy antigens to maternal brain-reactive antibodies
Betty A. Diamond, Bronx, NY (US); Simone Mader, Woodside, NY (US); Lior Brimberg, Bayside, NY (US); and Peter Gregersen, Larchmont, NY (US)
Assigned to The Feinstein Institutes for Medical Research, Manhasset, NY (US)
Filed by The Feinstein Institutes for Medical Research, Manhasset, NY (US)
Filed on Jun. 21, 2022, as Appl. No. 17/845,021.
Application 16/852,755 is a division of application No. 15/760,660, granted, now 10,654,919, issued on May 19, 2020, previously published as PCT/US2016/054651, filed on Sep. 30, 2016.
Application 17/845,021 is a continuation of application No. 16/852,755, filed on Apr. 20, 2020, granted, now 11,365,243.
Claims priority of provisional application 62/237,150, filed on Oct. 5, 2015.
Prior Publication US 2023/0067234 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 38/17 (2006.01); A61P 25/28 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61P 25/28 (2018.01); G01N 33/6896 (2013.01); G01N 33/6893 (2013.01); G01N 2800/28 (2013.01); G01N 2800/38 (2013.01); G01N 2800/50 (2013.01)] 10 Claims
 
1. A method of inhibiting or reducing development of an autism spectrum disorder in a fetus or an infant comprising administering to a mother pregnant with the fetus prior to the fetus being born as an infant, an amount of an agent comprising a peptide comprising the sequence of an extracellular portion of Potassium Voltage-Gated Channel Subfamily A Regulatory Beta Subunit 1 (KCNAB1) effective to inhibit or reduce development of an autism spectrum disorder in the fetus or the infant.